Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAP Regimen vs Disease-Specific Chemotherapy for Stem Cell Mobilization in NHL
NCT06520163Phase 3Recruiting
- Sponsor
- The Affiliated People’s Hospital of Ningbo University
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of etoposide, cytarabine, pegfilgrastim in non-Hodgkin lymphoma (NHL), sponsored by The Affiliated People’s Hospital of Ningbo University. Started Aug 2024; status: recruiting.
02
Drugs
etoposidecytarabinepegfilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06520163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520163.